Cytokinetics Ratings Boosted with $108 and $87 Price Targets on Myqorzo Launch
B. Riley initiated coverage with a Buy rating and $108 price target; Barclays launched Overweight with an $87 target. Myqorzo launched early 2026 offering streamlined REMS, zero pharmacy recalls, flexible echo windows and faster dose stabilization, targeting 5,000 churned patients from about 11,000 CAMZYOS users.
1. B. Riley Initiates Buy Rating
On February 4, B. Riley initiated coverage of Cytokinetics with a Buy rating and a $108 price target, citing the company’s potential to capture significant share in the cardiac myosin inhibitor market following Myqorzo’s launch.
2. Barclays Launches Overweight Rating
On January 28, Barclays assigned an Overweight rating with an $87 price target, highlighting the company’s prospects after introducing Myqorzo with a differentiated label designed to reduce echocardiogram monitoring requirements.
3. Myqorzo’s Competitive Advantages
Launched in early 2026 for obstructive hypertrophic cardiomyopathy, Myqorzo features a materially streamlined REMS, zero pharmacy recalls, flexible echo windows and faster dose stabilization, positioning it to capture approximately 5,000 churned patients from an estimated 11,000 existing CAMZYOS users.